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Abstract  
Raman spectroscopy was employed for the characterisation of blood plasma samples from patients 
at different stages of breast cancer. Blood plasma samples taken from clinically diagnosed breast 
cancer patients were compared with healthy controls using multivariate data analysis techniques 
(principal components analysis – PCA) to establishRaman spectral features which can be 
considered spectral markers of breast cancer development.All the stages of the disease can be 
differentiated from normal samples. It is also found that stage 2 and 3 are biochemically similar, 
but can be differentiated from each other by PCA. The Raman spectral data of the stage 4 is found 
to be biochemically distinct, but very variable between patients.Raman spectral features associated 
with DNA and proteins were identified, which are exclusive to patient plasma samples. Moreover, 
there are several other spectral features which are strikingly different in the blood plasma samples 
of different stages of breast cancer. In order to further explore the potential of Raman spectroscopy 
as the basis of a  minimally invasive screening technique for breast cancer diagnosis and staging, 
PCA-Factorial Discriminant Analysis (FDA) was employed to classify the Raman spectral 
datasetsof the blood plasma samples of the breast cancer patients, according to different stages of 
the disease, yielding promisingly high values of sensitivity and specificity for all stages. 
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 Introduction 
Breast cancer is a major threat to the health of women, primarily, all over the world. According to 
the International Agency for Research on Cancer(IARC), of all diagnosed cancers, about 11.9% 
(1.7 million cases)are of the breast[1]. Its incidence is spreading globally, except in the United 
States, where it is comparatively stable [2], and, in 2017, and estimated 250,000 diagnosed cases 
of female breast cancer and 40,000 associated deaths were reported[3].According to the U.S. 
National Cancer Institute, the associated cost of the care of breast cancer will reach approximately 
$20.5 billion in 2020 [4]. However, the survival is more favorable, although the mortality rateis 
lower in developed countries than developing regions [5]. The contribution of genetic factors in 
breast cancer is reported to be only 5-10% [6-7], posing a challenge for potential prevention. The 
variable risk factors may include late childbearing, lactation failure, weight gain after menopause, 
nulliparity, lack of exercise, and alcohol consumption [8]. Breast cancer cells develop in the tissue 
of the mammary gland and have an evolution period of 7 years, as 100-300 days are required to 
double the number of cancer cells and the emergence of breast neoplasm requires 30 doublings[9]. 
This highlights the potential importance of early detection and the developments of screening 
techniques which are capable of detecting the early stage abnormalities at a micro level. The 
different stages of cancer are an important element ofthediagnosis protocol, particularly for the 
survival prospects. The classification depends on the size of tumour (T), involvement of lymph 
nodes (N) and metastasis/no metastasis to other organs (M) [5]. In stage 0, caner has not developed 
further than the instigation point, while in stage 1, it has spread to some fatty breast tissues, it has 
become a bit bigger in size at stage 2 and has spread up to 3 lymph nodes, while in stage 3, it has 
spread to the chest wall. Critically at stage 4, also referred to as the metastatic phase, it has spread 
from the breast or lymph nodes to bones, liver, lungs and brains, beyond which there is no further 
stage classification. 
In the field of medicine/ clinical practice, the range of techniques which are currently used for the 
diagnosis and subsequent treatment of breast cancer include fluorescence, optical 
bioluminescence, optical imaging, MRI (magnetic resonance imaging), X-ray imaging and 
ultrasound [10-12]. These techniques have low sensitivity and resolution, and X-ray employs 
potentially harmful radiation which can be very risky for patients. Moreover, when visible on x- 
ray or MRI, the cancer is already at an advanced stage. There is a clinical need for a high 
sensitivity, real time, label free and less invasive method to screen patients for early stage 
symptoms, and also to establish the stage of development of the disease. 
Raman spectroscopy has been demonstrated to provide specific molecular signatures of a variety 
of biological samples and other materials [13-15]. It can detect changes of molecular composition 
and structure which take place during the formation of a tumour, in the constituents of cells and 
tissue such as nucleic acids, carbohydrates, proteins and lipids. Blood carries the metabolic 
products of a tumour which can be monitored during circulation. As these biochemical changes 
are manifest prior to the appearance of clinical symptoms commonly detected by medical imaging, 
Raman spectroscopy has the potential to provide early diagnosis of the cancer [16-22]. 
Regarding number of studies have already explored Raman spectroscopy for the diagnosis of 
breast cancer based on blood plasma/serum samples from clinically diagnosed patients. Bilal et al. 
applied Partial least squares(PLS) regression analysis to the Raman spectral data acquired from 
blood serum of breast cancer and healthy individuals and coefficients of regression were 
determined which are associated with the changes at the bio-molecular level, hence indicating the 
development of the disease[23]. In another study, Pichardo-Molina et al. applied Raman 
spectroscopy along with principal components analysis (PCA) and PCA-Linear Discriminate 
Analysis (LDA) to breast cancer and control blood samples, identifying specific bands which 
distinguish breast cancer blood serum samples from the healthy ones[24]. To date, however, to the 
best of our knowledge, there have been no reports in which the technique has been applied to 
differentiate the different stages of breast cancer by using blood plasma samples. 
In this study, Raman micro spectroscopy, supported by multivariate analyses, is employed to 
analyse the characteristic signatures of blood plasma samples from patients diagnosed with breast 
cancer of either stage 2, 3 or 4, and to differentiate them from both normal healthy controls and 
from each other. In doing so, the underlying biochemical origin of the differentiating features is 
explored, and the potentialof the technique for minimally invasive diagnosis and staging of the 
disease is demonstrated. 
 
Materials and methods 
Sample preparation and protocol 
Two groups were selected for study, which included 18 female patients with a confirmed clinical 
and histopathological diagnosis of breast cancer and 8 healthy/control subjects. Notably, the 
available breast cancer samples belong to stages 2, 3 and 4 with six, eight and four blood plasma 
samples respectively.Samples of stage-1 were not available, as patients rarely present to the clinic 
at this stage of the disease. Blood plasma samples were collected from breast cancer patients that 
were admitted to two hospitals; Allied and PINUM Hospital, Faisalabad and were approved for 
study by the Ethical Committee. Patients from both hospitals had similar socioeconomic and ethnic 
backgrounds. Blood samples were collected in Ethylene Diamine Tetra Acetic Acid (EDTA) vials 
and centrifuged at 3400 rpm for 5 min to yield the plasma samples. 
 
Raman spectral acquisition 
A 20 μl drop of each plasma sample was placed on an aluminium slide at room temperature and 
Raman spectra were acquired before the plasma sample had dried.The process of placing the 20μl 
drop on the aluminium slide was repeated 3 times, employing a clean aluminium slide each time, 
acquiring 20-25 spectra in total from each blood plasma sample. 
Raman spectral acquisition from all of the 19 female patients with a confirmed diagnosis of breast 
cancer and 8 healthy/control blood plasma samples was performed using a Raman micro 
spectrometer(Peak Seeker Pro-785; Agiltron, USA). The Peak Seeker Pro-785 utilises a 
785nmdiode laser as the source, deliveringa laser power of ~60 mW at the sample. The laser was 
delivered tothe sample through a 10× objective. The acquisition of the Raman spectra for all 
thesamples was executed from 600 to 1800 cm-1and 20–25 Ramanspectra per sample were 
acquired with an acquisition time of 30 second. 
The assignments of the Raman spectralfeatures used in interpretation of the results were taken 
from theliterature[25-29] and are described in Table 1. 
Data preprocessing 
All data processing of the Raman spectra was performed using Matlab 7.2 and established 
protocols [30]. Data pre-processing included smoothing, baseline correction, vector normalisation 
and substrate removal. All spectra, including substrate backgrounds, were vector normalised and 
smoothed using a Savitzky-Golay smoothing method (order 5,13 point window). A rubber band 
correction for baseline removal for all the spectra was carried out and the substrate spectra were 
subtracted from each spectrum. 
Data analysis  
Principal components analysis (PCA) is a mathematical procedure involvingthe transformation of 
possibly correlated variables into a smallernumber of uncorrelated variables, known as principal 
components(PC), basically to reduce the dimensionality of the data whilst maintainingtheir 
variability. The first principal component accounts forthe dominant source of variability in the 
data, and each successive principal component accounts for the next highest source of the 
remaining variability. PCA-Factorial Discriminant Analysis (FDA) has been employed to 
differentiate the Raman spectra based on the stage of the breast cancer, demonstrating the 
diagnostic potential of the technique. The discriminant analyses help to classify the unknown 
samples using prior knowledge of the category from training sets. To predict the association of the 
spectral data to a defined group (stage of the disease), the coupling of PCA with FDA makes use 
of the calculated PC scores to better evaluate the rate of discrimination acquired based on a data 
set [31]. The classification values obtained for each iterationare gathered to producea confusion 
matrix which is representative of the discrimination of the data. For this type of strategy, the model 
is restricted to a specified number of iterations, dictated by the number of patients. In present study, 
there are 27 groups of Raman spectra (8 healthy and patients with a confirmed clinical and 
histopathological diagnosis of breast cancer). 
 
Wavenumbers 
(cm-1) 
Peak assignments References 
625 Nucleotide conformation  [32] 
689 Nucleotide conformation [33] 
700 n (C-S) trans (aminoacid methionine) [34] 
714-6 C-N (membrane phospholipids head)/adenine  
CN2(CH3)3 (lipids) 
[35] 
761 Tryptophan, d (ring)  [34] 
770 Phosphate [36] 
778 Phosphatidylinositol  [37] 
788 phosphodiester bands in DNA  [38] 
798 CH out of plane deformation [39] 
828 tyrosine/protein [40] 
848 Most probably due to single bond stretching 
vibrations for the amino acids and valine. 
Tyrosine (Fermi resonance of ring fundamental 
and overtone) 
[41] 
 
[34] 
857 (collagen type I) [40] 
885 Disaccharide (cellobiose), (C-O-C) skeletal mode  [34] 
911 Glucose  [37] 
917 Proline, hydroxyproline [40] 
1100 C-C vibration mode of the gauche-bonded chain  [42] 
1138 n(C-C)-lipids, fatty acids  [34] 
1145 n(C-C)-lipids, fatty acids [34] 
1173 Cytosine, guanine  [43] 
1185 Anti-symmetric phosphate vibrations  [44] 
1268 d (=C-H) (phospholipids)  [45] 
1285 Typical phospholipids  [46] 
1307 CH3/CH2twisting, wagging &/or bending mode 
of collagens & lipids 
 
[40] 
1319 Guanine (B,Z-marker)  [43] 
1410 ns COO2 (IgG)  [45] 
1440 CH2 deformation in normal breast tissue  [47] 
1609 Cytosine (NH2) [43] 
1660-63 DNA  [48] 
 
Table 1: Assignments of the Raman spectral features, derived from literature. 
 
Results and discussion 
Figure 1 shows the mean Raman spectra with standard deviation of control and breast cancer blood 
plasma samples (mean Raman spectra of breast cancer stage-2, stage-3 and stage-4), and 
potentially differentiating features are indicated by vertical lines (Spectra have been offset for 
clarity). Raman spectral features, including those at 689 (nucleotide conformation), 770 
(phosphate), 788 (phosphodiester bands in DNA),828 (tyrosine/protein), 848 (single bond 
stretching vibrations for the amino acids and valine and polysaccharides), 885(disaccharide 
(cellobiose), (C-O-C) skeletal mode), 1138 (n(C-C)-lipids, fatty acids),1173(cytosine, guanine), 
1185 (anti-symmetric phosphate vibrations), 1268 (d (=C-H) (phospholipids)), 1285 (typical 
phospholipids), 1307 (CH3/CH2 twisting, wagging &/or bending modeof collagens & lipids) and 
1319cm-1 (guanine (B,Z-marker)) have higher intensities in the mean Raman spectra of patient 
samples. In contrast, the Raman spectral features at 700 (n (C-S) trans (aminoacid methionine)), 
761 (Tryptophan, d (ring)), 798 (CH out of plane deformation) and 1410 cm-1 (ns COO2) have 
higher intensities in the mean Raman spectra of control/healthy volunteers than in the patient 
samples.  
 Figure 1: Mean Raman spectra of control/healthy (black) and breast cancer (red) blood plasma 
samples. Spectra have been offset for clarity. 
Figure 2shows the PCA scatter plot of the Raman spectral data of the blood plasma samples of 
breast cancer patients of all different stages versus healthy ones. PC1 explains 79% of the variance, 
and shows reasonably good differentiation of the Raman spectral data of healthy and breast cancer 
patients. Stage 2 and Stage 3 samples are well differentiated from normal controls, but are largely 
overlapped, although it may be considered that the Stage 3 samples are more differentiated 
according to PC1. The overlap of the Stage 2 and 3 clusters indicates that, although they are 
clinically distinguished by the extent of the disease progression, they are spectrally, and therefore 
biochemically similar, in terms of their manifestation in the blood stream. Notably, the outlying 
clusters of the spectra have been identifiedas associated with the samples of stage-4,which are 
clustered according to individual patients. They are not significantly more differentiatedthan the 
other stages according to PC1, but are further differentiated according to PC2, indicating a distinct 
biochemical manifestation in the blood stream. 
 Figure 2: PCA scatter plot of Raman spectral data of healthy versus breast cancer samples. 
 
 Figure 3: PCA loadings of Raman spectral data of healthy versus different stages of breast cancer 
samples (a) PCA scatter plots of; control versus stage-2 (b), control versus stage-3 (c) and control 
versus stage-4 (d). 
 
Figure 3 represents the PCA scatter plots and loadings of the Raman spectral data of 
control/healthy versus each different stage of the breast cancer blood samples. The changes in 
biological molecules which are responsible for the clustering of healthy and cancerous samples in 
the PCA scatter plots are indicated by the loadings of the PC in Figure 3 (a).In all cases, positive 
loadings show the peaks of cancerous samples, while negative loadings represent the Raman 
spectral features associated with the healthy samples, as their respective Raman spectra are 
clustered in the positive and negative axis of the PC-1. The Raman spectral features, observed in 
positive loadings of all stages, include those at689 (Nucleotide conformation), 770 (phosphate), 
788 (phosphodiester bands in DNA),828 (tyrosine/protein), 848 (single bond stretching vibrations 
for amino acids and polysaccharides), 1138 (n(C-C)-lipids, fatty acids),1173(cytosine, guanine), 
1185 (anti-symmetric phosphate vibrations), 1268 (d (=C-H) (phospholipids)), 1285 (typical 
phospholipids) 1307 (CH3/CH2 twisting, wagging &/or bending modeof collagens & lipids) and 
1319 cm-1 (guanine (B,Z-marker)).Notably, these Raman featureswere also observed in figure 1 as 
elevated in the mean Raman spectra of breast cancer blood plasma samples, and therefore these 
positive loadings can be associated with the presence of disease. Similarly, in the negative 
loadings, the features at 700 (n (C-S) trans (aminoacid methionine)), 761 (Tryptophan, d (ring)), 
798 (CH out of plane deformation) and 1410 cm-1 (ns COO2) have higher intensities in mean 
Raman spectra of healthy volunteers than patient samples. Other Raman spectral features observed 
include those at 1100 cm-1 (C-C vibration mode of the gauche-bonded chain) as positive loadings 
and 1440 (CH2 deformation in normal breast tissue) and 1663 cm
-1 (DNA) as negative loadings. 
Moreover, Raman spectral features, including those at 689, 1138, 1173, 1185, 1268, 1319, 1440 
and 1663 cm-1, are elevated in breast cancer stage 4, and hence can be considered as a marker 
associated with the progression of disease. 
 
In Figure 4 (a),the PCA scatter plot shows the comparison of two different breast cancer stages, 
stage-2 and stage-3. The spectra of the different stages are differentiated according to PC2, 
indicating that Raman spectroscopy of the blood serum can differentiate these two stages of the 
disease. The positive loadings of PC2 is associated with the Raman features of stage-3, which have 
higher intensities than that of stage-2, including those at 625cm-1, 689cm-1 (nucleotides), 770 
(phosphate), 788 (phosphodiester bands in DNA), 828 (tyrosine/protein), 1285 (phospholipids) 
1307 (CH3/CH2 twisting, wagging and/or bending modeof collagens & lipids) and 1319 cm
-1 
(Guanine). 
Therefore, although stage 2 and stage 3 are not well distinguished in the overall comparison of all 
patient samples to normal controls (Figure 2), the two stages of disease development are well 
differentiated in a pairwise comparison (Figure 4 a). 
 
After thediagnosis of breast cancer, it is important to determine the staging of the cancer, because 
this will help to know that how far the disease has progressed and also to determine the best way 
to contain and eliminate the breast cancer.Stage 2 breast cancer is still in the earlier stages, but 
there is evidence that the cancer has begun to grow or spread. It is still contained to the breast area 
and is generally very effectively treated. On the other hand, stage 3 is known to be an advanced 
stage of breast cancer, at which the cancer has started to invade the surrounding tissues of the 
breast. In this regard, Raman spectroscopy can potentially be of benefit in the differentiation of 
these stages of breast cancer, hence leading to early diagnosis which could be useful for the 
effective treatment. The technique is shown to do this on the basis of the identification of the 
underlying biochemistry, the Raman spectral features, as indicated in (Figure 4 b). It is found that 
positive loadings of PC2 are associated with the Raman features of stage-3 which have higher 
intensities than that of stage-2, particularly those of nucleic acids. These features associated with 
DNA are very clear markers of cancer,as circulating DNA is only present in the blood plasma of 
the cancer patients. Moreover, this also indicates the progression from stage 2 to stage 3, as 
indicated by the dominant presence of these Raman features in the Raman spectra of the patients 
of stage-3 patients. 
 
 
 
 Figure 4: PCA scatter plot (a) and loading (b) of Raman spectral data of breast cancer samples 
of stage 2 verses stage 3. 
Figure 5 (a)showsthe PCA scatter plot of breast cancer stage-2 and stage-4 and it can be seen that 
Raman spectral data of the stage-2 (blue dots) is differentiated from that of the stage-4 (red dots) 
by clustering in the negative and positive axis of the PC-1 respectively. InFigure 5 (b),the 
differences observed as positive loadings have higher intensities in the Raman spectral data of 
stage-4 than stage-3 patients, including those at 689cm-1 (nucleotides), 1185 cm-1 (anti-symmetric 
phosphate vibrations), 1285 cm-1 (phospholipids) and 1319 cm-1 (guanine (B,Z-marker)).  
 
 
 Figure 5: PCA scatter plot (a) and loadings (b) of Raman spectral data of breast cancer samples 
of stage 2 verses stage 4. 
In Figure 6 (a) PCA scatter plot of stage-3 and stage-4 of the breast cancer is shown and separation 
between these two stages is observed according to PC-1, by clustering in the negative and positive 
axis respectively. In Figure 6 (b), which shows the loadings of the PC1, the positive loadings 
represent the Raman spectral features those have higher intensities in stage-4 as compared the 
stage-3. Notably, these Raman spectral features, including those at 689cm-1 (nucleotides), 1185 
cm-1 (anti-symmetric phosphate vibrations), 1285 cm-1 (phospholipids) and 1319 cm-1 (guanine), 
have also been observed (figure 5) as the features associated with stage-4 and in figure 4 these 
features have higher intensities in stage-3 as compared with stage-2. Hence, these changes 
observed in the stage wise comparison for the breast cancer indicate the biochemical changes 
taking place during the development and progression of breast cancer. 
In stage 4, thediseasehas spread to the surrounding tissues of the breast and it is considered the most 
advanced stage of breast cancer. It is very difficult to treat effectively at this stage of the cancer. 
The differentiation between Stage 2/3 and stage 4 is important because this can lead to early 
diagnosis which could be useful for the effective treatment.Notably, stage 2 is difficult to diagnose 
by histopathology unless a number of biopsies are taken. Moreover, this process is time consuming 
and histology protocols are not necessarily reliable. In this regard, Raman spectroscopic analysis 
of blood samples, a much more rapid analysis, is shown to be helpful in the detection of the early 
stage and differentiation of the later stages of breast cancer, predominantly on the basis of 
increasing DNA contentsduring the progression of the breast cancer from stage 2 to stage 4. The 
Raman spectral features, including those at 689cm-1 (nucleotides), 1185 cm-1 (Anti-symmetric 
phosphate vibrations), 1285 cm-1 (phospholipids) and 1319 cm-1 (Guanine), are observed (figure 
5) as the features associated with stage-4 and in figure 4 these features have higher intensities in 
stage-4 as compared with stage-2/3. Hence, these changes observed in the stage wise comparison 
for the breast cancer indicate the biochemical changes taking place during the development and 
progression of breast cancer. Notably, all the patients of the stage 4 are found very much distinct 
from each other, indicated by the clustering pattern of the Raman spectral data of this stage in the 
PCA scatter plots (Figure 5 a and Figure 6a) which may be due to the increase in the degree of the 
severity of the breast cancer, and the diversity of routes towards metastasis. 
 
This study advances previously published work related to the use of Raman spectroscopy for the 
characterization/diagnosis of breast cancer by using blood plasma/serum samples from clinically 
diagnosed patients, as the spectral markers of689 (Nucleotide conformation), 788 (phosphodiester 
bands in DNA), 828 (tyrosine/protein), 848 (most probably due to single bond stretching vibrations 
for amino acids and polysaccharides) and 1663 cm-1 (DNA) have not previously been identified. 
In these reports, Bilal et al. applied Partial least squares(PLS) regression analysis to the Raman 
spectral data acquired from blood serum of breast cancer and healthy individuals and coefficients 
of regression were determinedwith sensitivity of 90% and specificity 75% which are associated 
with the changes at the bio-molecular level [23], while in the current study sensitivity and 
specificity have been found to be as high as 100% in the comparison of control and breast cancer 
samples. In another study, Pichardo-Molina et al. applied Raman spectroscopy along with principal 
components analysis (PCA) and PCA-Linear Discriminate Analysis (LDA) to breast cancer and 
control blood samples, identifying specific bands which distinguish breast cancer blood serum 
samples from the healthy ones [24]. In the current study, the technique has been applied to 
differentiate the different stages of breast cancer by using blood plasma samples and such Raman 
spectral changes are observed in the stage wise comparison for the breast cancer which indicates 
the biochemical changes taking place during the development and progression of breast cancer 
through different stages. 
 
 
Figure 6: PCA scatter plot (a) and loadings (b) of Raman spectral data of breast cancer samples 
of stage 3 verses stage 4. 
In order to quantify the diagnostic potential of the spectroscopic technique, a further classification 
of the control and breast cancer using PCA-FDA was carried out. The results are shown in Table 
2, which indicates that the presence of breast cancer in patients can be detected in plasmawith a 
sensitivity of 100% and a specificity of 100%. Furthermore, PCA-FDA shows sensitivity 
99.65%and specificity 96.83% for breast cancer stage 2 versus stage 3/4 (Table 3), sensitivity 
96.3% and specificity 90.16% for breast cancer stage 3 versus stage 2/4 (Table 4) and sensitivity 
93.10% and specificity 91.11% for breast cancer stage 4 versus stage 2/3 (Table 5). 
 
 
 Normal Breast cancer Total/group Specificity 
Normal 175 0 175 100% 
Breast cancer 0 409 409 Sensitivity 
  Total spectra 
 
584 100% 
Table 2: Results of the PCA-FDA for the Raman spectral data of Normal versus all breast cancer 
(stage 2, 3&4) samples. 
 Breast cancer 
stage-2 
Breast cancer 
stage-3/4 
Total/group Specificity 
Breast cancer 
Stage-2 
122 4 126 99.65% 
Breast cancer 
stage-3/4 
1 282 283 Sensitivity 
  Total spectra 
 
409 96.83% 
 
Table 3: Results of the PCA-FDA for the Raman spectral data of breast cancer stage 2 versus stage 
3/4samples. 
 
 Breast cancer 
stage-3 
Breast cancer 
stage-2/4 
Total/group Specificity 
Breast cancer 
Stage-3 
174 19 193 96.3% 
Breast cancer 
stage-2/4 
8 208 216 Sensitivity 
  Total spectra 
 
409 90.16% 
 
Table 4: Results of the PCA-FDA for the Raman spectral data of breast cancer stage 3 versus stage 
2/4 samples. 
 
 Breast cancer 
stage-4 
Breast cancer 
stage-2/3 
Total/group Specificity 
Breast cancer 
Stage-4 
82 8 90 93.10% 
Breast cancer 
stage-2/3 
22 297 319 Sensitivity 
  Total spectra 
 
409 91.11% 
 
Table 5: Results of the PCA-FDA for the Raman spectral data of breast cancer stage 4 versus stage 
2/3samples. 
Conclusions 
Raman spectroscopy along PCA has shown its potential to be used for the diagnosis of breast 
cancer at an early stage, by employing blood plasma samples and healthy controlstaken from 
clinically diagnosed breast cancer patients. Among several, Raman spectral features associated 
with DNA and proteins are identified, which are solely observed in the blood plasma samplesof 
the breast cancer patients. Moreover, there are several other spectral features which are strikingly 
different in the blood plasma samples of different stages of breast cancer. Raman spectral data of 
different stages of the disease is compared by employing PCA. PCA scatter plots have shown clear 
differentiation between healthy and disease as well as different stages of breast cancer.The 
differentiation between Stage 2/3 and stage 4 is important because this can lead to early diagnosis 
which could be useful for the effective treatment. 
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